Journal Watch · Nature Biomedical Engineering · 2026
CAR-neutrophils produced in vivo to treat glioma.
These findings establish a programmable neutrophil platform for cancer immunotherapy.
TL;DR
These findings establish a programmable neutrophil platform for cancer immunotherapy.
Key findings
- The feasibility and safety of NeuSMRT are also demonstrated in experimental dogs.
- These findings establish a programmable neutrophil platform for cancer immunotherapy.
What they did
In a syngeneic glioma model, CAR-neutrophils produced in vivo significantly inhibit tumour growth and prolong survival, accompanied by enhanced T cell recruitment and activation, and reduced immunosuppression of myeloid cells in the tumour microenvironment. CAR-neutrophils further enhance the efficacy of chemotherapy and CAR-T therapy. Furthermore, CAR-neutrophils display antitumour activities in a humanized glioblastoma mouse model.
Full abstract (original)
Background: Despite their notable abundance in circulation and biological significance in the tumour microenvironment, direct genetic programming of neutrophils has been challenging. Here we develop a neutrophil-specific modified RNA translation platform, termed NeuSMRT, that enables the expression of chimeric antigen receptors (CARs) in primary neutrophils. NeuSMRT combines engineered extracellular vesicles or lipid nanoparticles for modified RNA delivery with a microRNA-responsive L7Ae:k-turn switch to restrict protein translation to neutrophils.
What they did: In a syngeneic glioma model, CAR-neutrophils produced in vivo significantly inhibit tumour growth and prolong survival, accompanied by enhanced T cell recruitment and activation, and reduced immunosuppression of myeloid cells in the tumour microenvironment. CAR-neutrophils further enhance the efficacy of chemotherapy and CAR-T therapy. Furthermore, CAR-neutrophils display antitumour activities in a humanized glioblastoma mouse model.
Results & conclusions: The feasibility and safety of NeuSMRT are also demonstrated in experimental dogs. These findings establish a programmable neutrophil platform for cancer immunotherapy.
Abstract © the authors / Nature Biomedical Engineering (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41551-026-01656-0 · PubMed 42032037.
Why it matters for pharma & biotech
- Directly relevant to teams in cell therapy (CAR-T / engineered cells), mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: cell therapy (CAR-T / engineered cells) · mRNA / delivery technology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Nature Biomedical Engineering study find?
These findings establish a programmable neutrophil platform for cancer immunotherapy.
What type of study is this?
It is a preclinical (animal / model) study, published in Nature Biomedical Engineering in 2026. In a syngeneic glioma model, CAR-neutrophils produced in vivo significantly inhibit tumour growth and prolong survival, accompanied by enhanced T cell recruitment and activation, and reduced immunosuppression of myeloid cells in the tumour microenvironment.
Where can I read the original paper?
The original is at the publisher via DOI 10.1038/s41551-026-01656-0. PubMed ID: 42032037. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/car-neutrophils-produced-in-vivo-to-treat-glioma-016560/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides